Blood coagulation protein conjugates
The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH 3 to form an alkoxyamine linkage.
1. A modified blood coagulation protein comprising:
a) a blood coagulation protein selected from the group consisting of
i) a blood coagulation protein with Factor IX (FIX) biological activity;
ii) a blood coagulation protein with Factor VIII (FVIII) biological activity;
iii) a blood coagulation protein with Factor Vila (FVIIa) biological activity;
iv) a blood coagulation protein with Von Willebrand Factor (VWF) biological activity;
v) a blood coagulation protein with Factor FV (FV) biological activity;
vi) a blood coagulation protein with Factor X (FX) biological activity;
vii) a blood coagulation protein with Factor XI (FXI) biological activity;
viii) a blood coagulation protein with Factor XII (FXII) biological activity;
ix) a blood coagulation protein with thrombin (FII) biological activity;
x) a blood coagulation protein with protein C biological activity;
xi) a blood coagulation protein with protein S biological activity;
xii) a blood coagulation protein with tPA biological activity;
xiii) a blood coagulation protein with PAI-1 biological activity;
xiv a blood coagulation protein with tissue factor (TF) biological activity; and
xv a blood coagulation protein with AD AMTS 13 protease biological activity; and
b) at least one water soluble polymer selected from the group consisting of polysialic acid (PSA), polysaccharides, pullulan, chitosan, hyaluronic acid, chondroitin sulfate, dermatan sulfate, starch, polyoxazoline, polyacryloylmorpholine, and polyphosphazene, and a linker bound to said blood coagulation protein of (a) at one or more carbohydrate moieties;
wherein the linker comprises 1-50 ethylene glycol units; and
wherein said modified blood coagulation protein has an oxime linkage between said one or more carbohydrate moieties and the linker on the water soluble polymer.
2. The modified blood coagulation protein of claim 1 , wherein said modified blood coagulation protein has a specific activity of at least 50% relative to an unmodified blood coagulation protein.
3. The modified blood coagulation protein of claim 1 , wherein said modified blood coagulation protein has a specific activity of at least 60% relative to an unmodified blood coagulation protein.
4. The modified blood coagulation protein of claim 1 , wherein said modified blood coagulation protein has a specific activity of at least 70% relative to an unmodified blood coagulation protein.
5. The modified blood coagulation protein of claim 1 , wherein said modified blood coagulation protein with Factor VIII (FVIII) biological activity.
6. The modified blood coagulation protein of claim 1 , wherein said modified blood coagulation protein with Factor IX (FIX) biological activity.
7. The modified blood coagulation protein of claim 1 , wherein the modified blood coagulation protein is a full-length blood coagulation protein.
8. The modified blood coagulation protein of claim 1 , wherein the oxidized carbohydrate moiety of the modified blood coagulation protein is located in the activation peptide of the blood coagulation protein.
9. The modified blood coagulation protein of claim 1 , wherein the linker has 2 or 4 ethylene glycol units.
10. The modified blood coagulation protein of claim 1 , wherein the water soluble polymer is PSA.
11. The modified blood coagulation protein of claim 10 , wherein the PSA is comprised of about 5-500 sialic acid units.
12. The modified blood coagulation protein of claim 10 , wherein the PSA is comprised of about 10-300 sialic acid units.
13. The modified blood coagulation protein of claim 10 , wherein the PSA has a molecular weight from 2,000 Da to 45,000 Da.
14. The modified blood coagulation protein of claim 10 , wherein the PSA has a molecular weight from 3,000 Da to 35,000 Da.
15. The modified blood coagulation protein of claim 10 , wherein the PSA has a molecular weight from 5,000 Da to 25,000 Da.
16. The modified blood coagulation protein of claim 1 , wherein the modified blood coagulation protein with FVIII biological activity and the linker comprises 1-50 ethylene glycol units.
17. The modified blood coagulation protein of claim 1 , wherein the modified blood coagulation protein with FVIII biological activity and the linker has 2 or 4 ethylene glycol units.
18. The modified blood coagulation protein of claim 1 , wherein the modified blood coagulation protein with FVIII biological activity and the linker has 2 or 4 ethylene glycol units.
19. The modified blood coagulation protein of claim 1 , wherein the modified blood coagulation protein with FVIII biological activity, the water soluble polymer is PSA having a molecular weight from 3,000 Da to 35,000 Da, and wherein the linker comprises 1-50 ethylene glycol units.
20. The modified blood coagulation protein of claim 1 , wherein the modified blood coagulation protein with FVIII biological activity, the water soluble polymer is PSA having a molecular weight from 3,000 Da to 35,000 Da, and wherein the linker has 2 or 4 ethylene glycol units.
21. The modified blood coagulation protein of claim 1 , wherein the modified blood coagulation protein with FVIII biological activity, the water soluble polymer is PSA having a molecular weight from 3,000 Da to 35,000 Da, wherein the linker comprises 1-50 ethylene glycol units, and wherein said modified blood coagulation protein has a specific activity of at least 50% relative to an unmodified blood coagulation protein.
22. The modified blood coagulation protein of claim 1 , wherein the modified blood coagulation protein with FVIII biological activity, the water soluble polymer is PSA having a molecular weight from 3,000 Da to 35,000 Da, wherein the linker has 2 or 4 ethylene glycol units, and wherein said modified blood coagulation protein has a specific activity of at least 50% relative to an unmodified blood coagulation protein.
23. The modified blood coagulation protein of claim 1 , wherein the modified blood coagulation protein with FIX biological activity and the linker comprises 1-50 ethylene glycol units.
24. The modified blood coagulation protein of claim 1 , wherein the modified blood coagulation protein with FIX biological activity and the linker has 2 or 4 ethylene glycol units.
25. The modified blood coagulation protein of claim 1 , wherein the modified blood coagulation protein with FIX biological activity and the linker has 2 or 4 ethylene glycol units.
26. The modified blood coagulation protein of claim 1 , wherein the modified blood coagulation protein with FIX biological activity, the water soluble polymer is PSA having a molecular weight from 3,000 Da to 35,000 Da, and wherein the linker comprises 1-50 ethylene glycol units.
27. The modified blood coagulation protein of claim 1 , wherein the modified blood coagulation protein with FIX biological activity, the water soluble polymer is PSA having a molecular weight from 3,000 Da to 35,000 Da, and wherein the linker has 2 or 4 ethylene glycol units.
28. The modified blood coagulation protein of claim 1 , wherein the modified blood coagulation protein with FIX biological activity, the water soluble polymer is PSA having a molecular weight from 3,000 Da to 35,000 Da, wherein the linker comprises 1-50 ethylene glycol units, and wherein said modified blood coagulation protein has a specific activity of at least 50% relative to an unmodified blood coagulation protein.
29. The modified blood coagulation protein of claim 1 , wherein the modified blood coagulation protein with FIX biological activity, the water soluble polymer is PSA having a molecular weight from 3,000 Da to 35,000 Da, wherein the linker has 2 or 4 ethylene glycol units, and wherein said modified blood coagulation protein has a specific activity of at least 50% relative to an unmodified blood coagulation protein.